Study suggests adult medulloblastoma patients should receive post-surgical adjuvant chemotherapy

Written by Peter Brown

Researchers from Yale Cancer Center (New Haven, CT, USA) have evaluated the survival impact of adjuvant chemotherapy in adult medulloblastoma (MB) patients. Chemotherapy is routinely utilized as treatment for pediatric MB, however the effectiveness in adult patients is unclear. The study, recently published in Neuro-Oncology and presented at the American Society for Therapeutic Radiology (25–28 September 2016, Boston, MA, USA), demonstrated that the addition of adjuvant chemotherapy as postoperative treatment for adult MB patients already receiving craniospinal radiation may improve survival rates. Utilizing the National Cancer Database, the team identified adult patients diagnosed with MB who underwent surgical resection and...

To view this content, please register now for access

It's completely free